Perspectives
Analytics show super spenders account for nearly 10% of total drug spend
Studies on members with drug costs over $250,000 yield predictive modeling data
February 21, 2021Ongoing studies using integrated benefits data on drug super spenders – members with total drug costs over $250,000 a year – provide predictive modeling data that can help manage outcomes and control costs
Ongoing studies using integrated benefits data on drug super spenders – members with total drug costs over $250,000 a year – provide predictive modeling data that can help manage outcomes and control costs
For many specialty conditions, nearly 90% of the total cost of care can come from drugs. That’s why Prime’s expertise at drug management is so important in controlling costs.
This study categorized and described trends in the medical conditions accounting for these member’s extraordinary drug expense.
This study contributes to Prime’s understanding of which drugs, conditions, and other factors can result in drug super spenders. It contributes to Prime’s ability to identify such members early by predictive modeling, and strategies to improve management of high cost specialty drugs. Integrated pharmacy claims analysis helps to confirm effectiveness of clinical programs and to identify additional opportunities.
Related news
Perspectives
July 25, 2024
Quarterly Drug Pipeline: July 2024
Clinical insights and competitive intelligence on anticipated drugs in development
Perspectives
July 22, 2024
Oncology Insights: 2024 ASCO Annual Meeting key findings
Findings from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting will likely lead to clinical practice changes and U.S. Food and Drug Administration (FDA) drug approvals or expansions
Perspectives
July 16, 2024
LISTEN NOW: Beyond the business – Stories of corporate kindness | Pharmacy Friends Podcast
In this episode, we talk about how our employees' help goes beyond our work in health care, aiding in philanthropic efforts